Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669538 · ClinicalTrials.gov registry record · Phase 2
Effect of Galantamine on Short-term Abstinence
A Phase 2 study of Tobacco Use Disorder, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT01669538: Completed Phase 2 study of Tobacco Use Disorder, sponsored by University of Pennsylvania.
NCT01669538 is a Phase 2 study of Tobacco Use Disorder that has completed, run by University of Pennsylvania. The registered enrollment target is 98 participants, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01669538, a Phase 2 study of Tobacco Use Disorder, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled study to test whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Galantamine
Study Locations (1)
Pennsylvania
- Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01669538
The ClinicalTrials.gov registry entry for NCT01669538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (59% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01669538 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01669538 about?
NCT01669538 is a clinical study titled "Effect of Galantamine on Short-term Abstinence". This is a randomized, double-blind, placebo-controlled study to test whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.
What is the current status of trial NCT01669538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2012-08. Estimated completion is 2017-11.
What conditions does trial NCT01669538 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT01669538?
The interventions under investigation include: Placebo (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT01669538?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01669538 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.